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The prostacyclin receptor (IP) is primarily coupled to
Gs-dependent activation of adenylyl cyclase; however,
a number of studies indicate that the IP may couple to
other secondary effector systems perhaps in a species-
specific manner. In the current study, we investigated
the specificity of G protein:effector coupling by the
mouse (m) IP overexpressed in human embryonic kid-
ney 293 cells and endogenously expressed in murine
erythroleukemia cells. The mIP exhibited efficient Gs
coupling and concentration-dependent increases in
cAMP generation in response to the IP agonist cica-
prost; however, mIP also coupled to Gi decreasing the
levels of cAMP in forskolin-treated cells. mIP coupling
to Gi was pertussis toxin-sensitive and was dependent
on protein kinase (PK) A activation status. In addition,
the mIP coupled to phospholipase C (PLC) activation in
a pertussis toxin-insensitive, Gi-, G-, and PKC-inde-
pendent but in a Gq- and PKA-dependent manner.
Whole cell phosphorylation assays demonstrated that
the mIP undergoes cicaprost-induced PKA phosphoryl-
ation. mIPS357A, a site-directed mutant of mIP, effi-
ciently coupled to Gs but failed to couple to Gi or to
efficiently couple to Gq:PLC. Moreover, mIP
S357A did
not undergo cicaprost-induced phosphorylation con-
firming that Ser357 is the target residue for PKA-depend-
ent phosphorylation. Finally, co-precipitation experi-
ments permitted the detection of Gs, Gi, and Gq in
the immunoprecipitates of mIP, whereas only Gs was
co-precipitated with mIPS357A indicating that Ser357 of
mIP is essential for Gi and Gq interaction. Moreover,
inhibition of PKA blocked co-precipitation of mIP with
Gi or Gq. Taken together our data indicate that the
mIP, in addition to coupling to Gs, couples to Gi and
Gq; however, Gi and Gq coupling is dependent on
initial cicaprost-induced mIP:Gs coupling and phos-
phorylation of mIP by cAMP-dependent PKA where
Ser357 was identified as the target residue for PKA
phosphorylation.
The prostanoid prostacyclin (prostaglandin I2), mainly pro-
duced by the vascular endothelium, plays a key role in the local
control of vascular hemostasis acting as a potent inhibitor of
platelet aggregation and as a vasodilator (1, 2). The actions of
prostacyclin generally counteract those of thromboxane A2, and
thus, the relative levels of these two prostanoids in the circu-
lation are central to the maintenance of vascular hemostasis
and vessel tone (3). Prostacyclin also exhibits proinflammatory
and antiproliferative properties in vitro (4, 5) and may confer a
cytoprotective effect against tissue injury during acute myocar-
dial ischemia or in response to hypoxia (6).
Prostacyclin signals through interaction with its signature G
protein-coupled receptor (GPCR)1 termed IP (7). The prostacy-
clin receptor (IP) is primarily coupled to activation of adenylyl
cyclase via Gs (3, 8, 9). Additional evidence indicates that the IP
may couple to multiple G protein:effector systems including
Gq-dependent activation of PLC and to mobilization of intra-
cellular calcium (10–13). Iloprost, a stable carbacyclin ana-
logue of prostacyclin, can stimulate the opening of ATP-sensi-
tive K channels resulting in hyperpolarization and relaxation
of the canine carotid artery (14). The IP agonists iloprost and
cicaprost were shown to stimulate the GTPase activity of both
Gs and Gi suggesting that the IP expressed in human erythro-
leukemia cells may potentially lead to activation and inhibition
of adenylyl cyclase, respectively (15). On the other hand, the IP
expressed in the rat medullary thick ascending limb coupled
exclusively to Gi inhibiting adenylyl cyclase as opposed to Gs
(16).
We have recently established that the IP may be unique
among GPCRs in that it is isoprenylated (12). Whereas isopre-
nylation of mouse (m) IP is not required for ligand binding, it is
absolutely required for its activation of adenylyl cyclase and for
its efficient coupling to PLC (12, 13). In addition, a number of
studies have confirmed that the IP undergoes rapid agonist-
induced receptor phosphorylation, internalization/sequestra-
tion, and down-regulation in human platelets and other cell
types (10, 17–20).
Whereas the primary manifestation of GPCR phosphoryla-
tion and sequestration was classically thought to be desensiti-
zation or dampening of the signal following agonist engage-
ment, there is increasing evidence that this is not exclusively so
(21). In fact, it is now widely held, for certain GPCRs at least,
that “desensitization of the primary signaling event” may trig-
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ger the “activation of (an)other secondary signaling cascade(s)”
(21). For example, for many GPCRs, receptor phosphorylation
and subsequent internalization has been shown to be essential
for GPCR activation of the mitogen-activated protein kinase
cascades and for transactivation of growth factor receptors (22).
Moreover, in a limited number of cases, agonist-mediated re-
ceptor phosphorylation has been reported to trigger molecular
switching whereby a receptor alters its coupling from one G
protein:effector system to a different G protein:effector system
(23, 24). Such molecular switching can facilitate GPCR cou-
pling to more than one G protein:effector system (21).
The molecular mechanisms whereby a single IP can couple to
more than one G protein:effector system has not been explored
in detail. Thus, in the present study we investigated the G
protein coupling characteristics of the mIP stably overex-
pressed in human embryonic kidney (HEK) 293 cells and in
murine erythroleukemia (MEL) cells, which endogenously ex-
press mIP. Our studies confirmed that mIP, in addition to its
coupling to Gs, may also couple Gi and Gq through a mech-
anism involving initial Gs signaling and cAMP-dependent
protein kinase (PK) A phosphorylation of mIP at Ser357 within
its C-tail region; thereafter the phosphorylated mIP exhibited
coupling to pertussis toxin (PTx)-sensitive Gi and inhibition of
adenylyl cyclase and to Gq-mediated activation of PLC. These
studies provide essential evidence demonstrating that agonist
activation of the classical Gs-coupled mIP can trigger its phos-
phorylation and, in turn, favor its signaling to Gi- and Gq-
coupled signal transduction cascades.
EXPERIMENTAL PROCEDURES
Materials
Cicaprost was obtained from Schering AG (Berlin, Germany). Ilo-
prost, [3H]iloprost (15.3 Ci/mmol), and [3H]CGP-12177 (41.0 Ci/mmol)
were purchased from Amersham Pharmacia Biotech. Fura2/AM, D-myo-
inositol 1,4,5-trisphosphate, and its 3-deoxyhexasodium salt (stable
analogue of IP3) were purchased from Calbiochem. [
32P]Orthophos-
phate (8,000–9,000 Ci/mmol) was obtained from PerkinElmer Life Sci-
ences. Isoproterenol was purchased from Sigma. [3H]IP3 (20–40 Ci/
mmol) and [3H]cAMP (15–30 Ci/mmol) were purchased from American
Radiolabeled Chemicals Inc. Polyvinylidene difluoride (PVDF) filters,
Taq DNA polymerase, the chemiluminescence Western blotting kit, and
rat monoclonal 3F10 anti-hemagglutinin (HA) peroxidase-conjugated
antibody were purchased from Roche Molecular Biochemicals. Oligonu-
cleotides were synthesized by Genosys Biotechnologies. Anti-Gs (K-
20), Gq/11 (C-19), and Gi-1 (I-20) antisera, horseradish peroxidase-
conjugated goat anti-rabbit IgG, and anti-G protein-coupled receptor
kinase 2 (C-15) antibody, raised against the carboxyl terminus of the
-adrenergic receptor kinase 1, were obtained from Santa Cruz Biotech-
nology. Mouse monoclonal 101R anti-HA antibody was obtained from
BabCO.
Materials and Methods
Site-directed Mutagenesis of the mIP—Conversion of Ser357 of the
mIP to Ala357, herein designated mIPS357A, was performed using the
Stratagene Quick Change site-directed mutagenesis kit using pHM:
mIP (12) as template and oligonucleotides 5-CTT TCC AGA CCT GCA
GCG GGG AGA AGA GAC C-3 (sense primer) and 5-G GTC TCT TCT
CCC CGC TGC AGG TCT GGA AAG-3 (antisense primer, the sequence
complimentary to mutator Ser (TCG) to Ala (GCG) codon is in boldface
italics). The plasmid was verified by double-stranded DNA sequencing
using Sequenase Version 2.0 (United States Biochemical Corp.). The
plasmid pRK5ARK1-(495–689) encoding the carboxyl-terminal
amino acid residues 495–689 of ARK1 (25) was kindly provided by
Prof. Robert Lefkowitz, Howard Hughes Medical Institute, Duke
University Medical Center. The plasmid pCMVGi was generated by
subcloning the full-length cDNA for rat Gi-1 into the EcoRI site of
pCMV5. The plasmids pCMVGq and pCMVGs have been described
previously (12, 26).
Cell Culture and Transfections—MEL clone 707 cells and HEK 293
cells were obtained from the American Type Culture Collection and
were maintained at 37 °C in 5% CO2. MEL cells were routinely cultured
in Dulbecco’s modified Eagle’s medium, 20% fetal bovine serum. HEK
293 cells were cultured in minimal essential medium with Earle’s salts
and 10% fetal bovine serum.
HEK 293 cells were transfected with 10 g of pADVA and 25 g of
pCMV- or pHM-based vectors using the calcium phosphate/DNA co-
precipitation procedure (26). For transient transfections, cells were
harvested 48 h after transfection. HEK.mIP, HEK.HAmIP,
HEK.mIPSSLC, and HEK.2AR cell lines have been previously described
(12). To create the HEK.HAmIPS357A stable cell line, HEK 293 cells
were transfected with 10 g of ScaI-linearized pADVA plus 25 g of
PvuI-linearized pHM:mIPS357A. Forty-eight hours post-transfection,
G418 (0.8 mg/ml) selection was applied. After21 days, G418-resistant
colonies were selected, and individual HEK.HAmIPS357A pure clonal
stable cell lines or isolates were examined for IP expression by radiolig-
and binding. All isolates used throughout the study were derived from
pure clonal stable cell lines.
Radioligand Binding Studies—Cells were harvested by centrifuga-
tion at 500  g at 4 °C for 5 min and washed three times with phos-
phate-buffered saline. For membrane preparation, cells were resus-
pended in Homogenization Buffer (25 mM Tris-HCl, pH 7.5, 0.25 M
sucrose, 10 mM MgCl2, 1 mM EDTA, 0.1 mM phenylmethylsulfonyl
fluoride), and membrane fractions were prepared by homogenization
followed by centrifugation (100,000  g, 40 min at 4 °C). The pellet
fraction (P100), representing crude membranes, was resuspended in
Resuspension Buffer (10 mM MES-KOH, pH 6.0, 10 mM MnCl2, 1 mM
EDTA, 10 mM indomethacin). IP radioligand binding assays were car-
ried out at 30 °C for 1 h using 100 g of membrane protein (P100) in
100-l reactions in the presence of 4 nM [3H]iloprost (15.3 Ci/mmol) as
described previously (12). 2-Adrenergic receptor (2AR) radioligand
binding assays were carried out on whole cells using 25 nM [3H]CGP-
12177 (41.0 Ci/mmol) at 14 °C for 3 h using 100 g of protein in a final
volume of 100 l essentially as described previously (27). Protein de-
terminations were carried out using the Bradford assay (28).
Measurement of cAMP—cAMP assays were carried out as described
previously (12). Briefly, cells were harvested by scraping and were
washed three times in ice-cold phosphate-buffered saline. Cells (1–2
106 cells) were resuspended in 200 l of HEPES-buffered saline (HBS;
140 mM NaCl, 4.7 mM KCl, 2.2 mM CaCl2, 1.2 mM KH2PO4, 11 mM
glucose, 15 mM HEPES-NaOH, pH 7.4) containing 1 mM 3-isobutyl-1-
methylxanthine and were preincubated at 37 °C for 10 min. Thereafter
ligands (50 l) were added, and cells were stimulated at 37 °C for 10
min in the presence of the ligand (1 M cicaprost, 10 M forskolin, 1 M
cicaprost plus 10 M forskolin, 10 M isoproterenol, or 10 M isoproter-
enol plus 10 M forskolin). For concentration-response studies, cells
were stimulated with 1 pM–1 M cicaprost. As controls, cells were
incubated in the presence of 50 l of HBS in the absence of ligand. To
investigate the effect of PTx, cells were preincubated with PTx (50
ng/ml) for 16 h prior to stimulation with the respective ligand. To
investigate the effect of kinase inhibitors on cAMP generation, cells
were preincubated in the presence of GF 109203X (50 nM), H-89 (10 M),
or vehicle (HBS) at 37 °C for 10 min prior to stimulation with the
respective ligand. In separate experiments, to examine the effect of
co-transfection of Gs on cAMP generation, HEK 293,
HEK.mIP, and HEK.mIPS357A cells were transiently co-transfected
with pCMVGs (25 g/10-cm dish) plus pADVA (10 g/10-cm dish).
In each case, cAMP reactions were terminated by heat inactivation at
100 °C for 5 min, and the level of cAMP produced was quantified using
the cAMP-binding protein assay (12). Levels of cAMP produced by
ligand-treated cells over basal stimulation, determined in the presence
of HBS, were expressed as pmol of cAMP/mg of cell protein  S.E.
Results are expressed as -fold stimulation relative to basal (-fold in-
crease  S.E.). Data were analyzed using the unpaired Student’s t test.
p values of less than or equal to 0.05 were considered to indicate a
statistically significant difference.
Measurement of IP3 Levels—Intracellular IP3 levels were measured
as described previously (29, 30). Briefly, cells were harvested, washed
twice in ice-cold phosphate-buffered saline and were then resuspended
at 5  106 cells/ml in HBS containing 10 mM LiCl. To investigate the
effect of PTx, cells were preincubated with PTx (50 ng/ml) for 16 h prior
to harvesting. To investigate the effect of the kinase inhibitors, H-89 (10
M) or GF 109203X (50 nM) was added, and the cells were incubated for
5 min at 37 °C in 5% CO2 prior to harvesting. Cells (200 l) were then
preincubated at 37 °C for 10 min. Thereafter cells were stimulated for
2 min at 37 °C in the presence of cicaprost (1 M), or for concentration-
response studies, cells were stimulated with 1 nM–10 M cicaprost. To
determine basal IP3 levels, cells were incubated in the presence of an
equivalent volume (50 l) of the vehicle HBS. To examine the effect of
co-transfection of Gq on IP3 generation, HEK.mIP cells were tran-
siently co-transfected with pCMVGq (12) (25 g/10-cm dish) and
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pADVA (10 g/10-cm dish). The IP3 levels produced were determined
using the IP3-binding protein assay (29, 30). Levels of IP3 produced by
ligand-stimulated cells over basal stimulation in the presence of HBS
were expressed in pmol of IP3/mg of cell protein  S.E., and results are
presented as -fold stimulation over basal (-fold increase  S.E.). The
data presented are representative of four independent experiments,
each performed in duplicate.
Measurement of Intracellular [Ca2] Mobilization—Measurements of
[Ca2]i in Fura2/AM-preloaded cells were carried out essentially as
described previously (26). To investigate the effect of PTx, cells were
preincubated with PTx (50 ng/ml) at 37 °C in 5% CO2 for 16 h prior to
stimulation with cicaprost (1 M). Where appropriate, the PKA (H-89,
10 M) or PKC (GF 109203X, 50 nM) kinase inhibitors were added 2 min
prior to stimulation with cicaprost (1 M). The phosphatidylinositol-
specific phospholipase C (PI-PLC) (U73122, 1 M) and phosphatidylcho-
line-specific phospholipase C (D-609, 10 M) inhibitors were added 5
min prior to stimulation of cells with cicaprost (1 M). Drugs and
inhibitors, with stock solutions dissolved in ethanol or dimethyl sulfox-
ide, were diluted in HBSSHB (modified Ca2/Mg2-free Hanks’ buff-
ered salt solution containing 20 mM HEPES, pH 7.67, 0.1% bovine
serum albumin plus 1 mM CaCl2) to the appropriate concentration such
that the addition of 20 l of the diluted drug/inhibitor to 2 ml of cells
resulted in the correct working concentration. In separate experiments
to examine the effect of G on [Ca2]i mobilization, HEK.mIP cells
were transiently co-transfected with the plasmid pRK5ARK1-(495–
689) encoding amino acid residues 459–689 from the C-tail of ARK1
(25 g/10-cm dish) plus pADVA (10 g/10-cm dish). For each [Ca2]i
measurement, calibration of the fluorescence signal was performed in
0.2% Triton X-100 to obtain the maximal fluorescence (Rmax) and 1 mM
EGTA to obtain the minimal fluorescence (Rmin). The ratio of the fluo-
rescence at 340 and 380 nm is a measure of [Ca2]i assuming a Kd of 225
nM Ca2 for Fura2/AM. The results presented in the figures are repre-
sentative data from at least four independent experiments and were
plotted as changes () in [Ca2]i mobilized as a function of time (s) upon
ligand stimulation or, alternatively, were calculated as mean changes
in [Ca2]i mobilized ([Ca
2]i  S.E.; n  4).
Western Blot Analysis—HEK.HAmIP or HEK.HAmIPS357A cells were
transfected with 10 g of pADVA and 25 g of pRK5ARK1-(459–689)
or 25 g of pCMVGs, pCMVGi, or pCMVGq using the calcium
phosphate/DNA co-precipitation procedure (26). Cells were harvested
48 h post-transfection, and aliquots of whole cell protein (75 g) were
resuspended in 1 Solubilization Buffer (10% -mercaptoethanol (v/v),
2% SDS (w/v), 30% glycerol (v/v), 0.025% bromphenol blue (w/v), 50 mM
Tris-HCl, pH 6.8; 100 l) and boiled for 5 min. Samples were then
resolved by SDS-polyacrylamide gel electrophoresis (PAGE) and were
electroblotted onto PVDF membranes (12). Thereafter membranes were
screened by immunoblot analysis using either the anti-G protein-cou-
pled receptor kinase 2 (C-15; 1:2000) antibody, directed against the
carboxyl terminus of ARK1, or the appropriate anti-Gs (K-20) (1:
3000), Gq/11 (C-19) (1:3000), or Gi-1 (I-20) (1:500) antisera. Horsera-
dish peroxidase-conjugated goat anti-rabbit IgG (1:3000) was used as
the secondary antibody in each case. Proteins were visualized using the
chemiluminescence detection system according to the manufacturer’s
recommendations.
Measurement of Agonist-mediated IP Phosphorylation in Whole
Cells—Agonist-mediated IP phosphorylations in whole HEK.HAmIP
(isolate 2 cells) and HEK.HAmIPS357A cells were carried out essentially
as described previously (29). Briefly, cells were washed once in phos-
phate-free Dulbecco’s modified Eagle’s medium containing 10% dia-
lyzed fetal bovine serum and were metabolically labeled for 1 h in the
same media (1.5 ml/10-cm dish) containing 100 Ci/ml [32P]orthophos-
phate (8,000–9,000 Ci/mmol) at 37 °C in 5% CO2. Where appropriate,
H-89 (10 M), GF 109203X (50 nM), or the vehicle HBS was added for
the duration of the labeling period. Thereafter 1 M cicaprost or the
vehicle HBS was added for 10 min at 37 °C in 5% CO2. Metabolic
labeling of cells was terminated by transferring the dishes to ice and
aspiration of the medium. Thereafter cells were quickly washed once in
ice-cold phosphate-buffered saline (2 ml/dish) and were lysed with 0.6
ml of Radioimmune Precipitation Buffer (50 mM Tris-HCl, pH 8.0, 150
mM NaCl, 1 mM EDTA, 1% Nonidet P-40 (v/v), 0.5% sodium deoxy-
cholate (w/v), 0.1% SDS (w/v) containing 10 mM sodium fluoride, 25 mM
sodium pyrophosphate, 10 mM ATP, 1 g/ml leupeptin, 10 g/ml soy-
bean trypsin inhibitor, 1 mM benzamidine hydrochloride, 0.5 mM phen-
ylmethylsulfonyl fluoride, 1 mM sodium orthovanadate). Following a
15-min incubation on ice, cells were harvested and disrupted by sequen-
tially passing through hypodermic needles of decreasing bore size (G20,
G21, G23, and G26), and soluble cell lysates were harvested by centrif-
ugation for 15 min at 13,000  g at room temperature. HA epitope-
tagged IP receptors were immunoprecipitated using the anti-HA anti-
body (101R, 1:300 dilution) at room temperature for 2 h followed by the
addition of 10 l of protein G-Sepharose 4B (Sigma) and further incu-
bation at room temperature for 1 h. Immune complexes were collected
by centrifugation at 13,000 g at room temperature for 5 min and were
washed three times in 0.3 ml of Radioimmune Precipitation Buffer and
were finally resuspended in 1 Solubilization Buffer (10% -mercapto-
ethanol (v/v), 2% SDS (w/v), 30% glycerol (v/v), 0.025% bromphenol blue
(w/v), 50 mM Tris-HCl, pH 6.8; 60 l). Samples were boiled for 5 min and
then loaded onto 10% polyacrylamide gels, analyzed by SDS-PAGE, and
thereafter electroblotted onto PVDF membranes essentially as de-
scribed previously (12). Electroblots were then exposed to Eastman
Kodak X-Omat XAR film to detect 32P-labeled proteins. Thereafter blots
were subjected to PhosphorImager analysis, and the intensities of phos-
phorylation relative to basal phosphorylation were determined and
were expressed in arbitrary units of intensity relative to basal levels. In
parallel experiments, cells were incubated under identical conditions in
the absence of [32P]orthophosphate. HAmIP and HAmIPS357A receptors
were immunoprecipitated, and immunoblots were screened using the
anti-HA 3F10 horseradish peroxidase-conjugated antibody (1:500) to
check for quantitative recovery of each receptor type. Immunoreactive
proteins were visualized using the chemiluminescence detection system
(12).
Co-immunoprecipations of the mIP and Its Associated G Proteins—
HEK.HAmIP and HEK.HAmIPS357A cells were transiently co-trans-
fected with the respective pCMVG plasmids encoding Gs, Gi, and
Gq (25 g/10-cm dish) and pADVA (10 g/10-cm dish). Approximately
48 h post-transfection, cells were either preincubated for 10 min with 10
M H-89 or, as a control, with an equivalent volume of the vehicle HBS
at 37 °C in 5% CO2 prior to stimulation with 1 M cicaprost for 10 min
at 37 °C in 5% CO2. Reactions were terminated, and HA-tagged IP
receptors were immunoprecipitated using the anti-HA 101R antibody
(1:300), blotted, and analyzed essentially as described previously (12).
Samples were resuspended in 1 Solubilization Buffer, boiled for 5 min,
then analyzed by SDS-PAGE on 10% polyacrylamide gels, and thereaf-
ter electroblotted onto PVDF membranes. Membranes were then
screened by immunoblot analysis using the appropriate Gs (K-20)
(1:3000), Gq/11 (C-19) (1:3000), or Gi-1 (I-20) (1:500) antisera where
horseradish peroxidase-conjugated goat anti-rabbit IgG (1:3000) was
the secondary antibody used in each case. Immunoreactive proteins
were visualized using the chemiluminescence detection system accord-
ing to the manufacturer’s recommendations.
Data Analyses
Statistical analysis was carried out using the unpaired Student’s t
test using GraphPad Prism Version 2.0 (GraphPad Software Inc., San
Diego, CA). p values of less than or equal to 0.05 were considered to
indicate a statistically significant difference.
RESULTS
Mouse Prostacyclin Receptor G Protein Coupling in Response
to Adenylyl Cyclase Activation—In the current study we sought
to investigate the specificity of G protein:effector coupling by
the mIP and to define the mechanism(s) whereby the mIP may
couple to more than one G protein:effector system. In addition,
as a comparative control, we investigated signaling by the
2AR, which has been reported to switch coupling from Gs to
Gi in a PKA-dependent mechanism (23). Thus, our studies
were performed in HEK 293 cells stably overexpressing the
mIP (HEK.mIP cells), in MEL cells that endogenously express
mIP, and in HEK.2AR cells stably overexpressing the human
2AR (12). Initially radioligand binding assays established mIP
expression levels in HEK.mIP cells and in MEL cells and 2AR
expression levels in HEK.2AR cells (Table I). Thereafter ago-
nist-induced cAMP generation was determined in HEK.mIP
cells (Fig. 1A) and in MEL cells (Fig. 1B) or in HEK.2AR cells
(Fig. 1C) in response to stimulation of cells with the selective IP
agonist cicaprost or the 2AR agonist isoproterenol in the ab-
sence or presence of the diterpene forskolin to detect Gi cou-
pling should it occur. Stimulation of HEK.mIP (p 0.0001) and
MEL (p  0.0001) cells resulted in significant increases in
cAMP generation consistent with mIP coupling to Gs.
Whereas incubation of cells with forskolin resulted in agonist-
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independent increases in cAMP generation, co-incubation with
cicaprost and forskolin caused significant decreases in cAMP in
both HEK.mIP (p  0.0001) and MEL (p  0.0001) cells. These
results suggest that the mIP can couple to both Gs and Gi.
Similar results were obtained upon examining cAMP gener-
ated by the 2AR (Fig. 1C), consistent with previous reports
that the 2AR may couple to both Gs and Gi (23).
Preincubation of HEK.mIP (Fig. 2A) or HEK.2AR (Fig. 2D)
cells with PTx abolished both mIP (p  0.001) and 2AR (p 
0.001) coupling to Gi. Whereas preincubation of either HEK.mIP
(Fig. 2B) or HEK.2AR (Fig. 2E) cells with the PKA inhibitor
H-89 prior to agonist stimulation had no effect on mIP- or
2AR-induced cAMP generation, it abolished the mIP and
2AR coupling to Gi (HEK.mIP, p  0.001; HEK.2AR, p 
0.001). On the other hand, the PKC inhibitor GF 109203X (Fig.
2, panels C and F) had no significant effect on either Gs or Gi
coupling by either the mIP (Fig. 2C, p  0.3988) or the 2AR
(Fig. 2F, p  0.5257).
To determine whether the mIP:Gi coupling is dependent on
the concentration of ligand used for stimulation, HEK.mIP
cells were stimulated with cicaprost (1 pM–1 M) in the absence
and presence of forskolin (Fig. 3A). mIP generated significant
concentration-dependent increases in cAMP consistent with its
coupling to Gs. However, in cells co-incubated with forskolin,
1 pM–1 nM cicaprost led to concentration-dependent augmenta-
tions of cAMP generation consistent with mIP coupling to Gs;
however, at the higher cicaprost concentrations (	1 nM), cica-
prost led to a concentration-dependent reduction in cAMP gen-
eration indicative of mIP coupling to Gi. In the presence of
PTx, cicaprost led to concentration-dependent increases in
cAMP generation in the presence (Fig. 3B) and absence of
forskolin (data not shown) over the complete range of cicaprost
concentrations (1 pM–1 M). Moreover, in the presence of H-89,
cicaprost resulted in concentration-dependent increases in
cAMP generation in the presence (Fig. 3B) and absence of
forskolin (data not shown) over the complete range of cicaprost
concentrations providing further evidence that Gi coupling by
mIP is dependent on PKA activation status.
Mouse Prostacyclin Receptor Coupling to PLC—We extended
these studies to investigate the mechanism whereby the Gs-
coupled mIP may also couple to the Gq:PLC effector system
(12). Stimulation of cells with cicaprost resulted in a significant
increase in IP3 generation in HEK.mIP cells compared with
control, nontransfected HEK 293 cells (Figs. 4A and 10A, p 
0.0009). Preincubation of HEK.mIP cells with PTx or GF
109203X had no significant effect on IP3 generation (PTx, p 	
0.911; GF 109203X, p 	 0.668); however, preincubation with
H-89 significantly decreased cicaprost-induced IP3 generation
(p 0.005). Because the levels of cicaprost-stimulated IP3 were
quite low (1.56  0.13-fold increase in IP3 in response to 1 M
cicaprost), HEK.mIP cells were transiently co-transfected with
Gq to increase the levels of measurable IP3 (Fig. 4B). Overex-
pression of Gq was confirmed by Western blot analysis using
anti-Gq-specific antisera (Fig. 4C). The presence of Gq aug-
mented (p  0.002) and led to a significant increase in cica-
prost-induced IP3 generation (Fig. 4B), and cicaprost-induced
IP3 generation in the presence of Gq was not affected by
preincubation with either PTx (p 	 0.812) or GF 109203X (p 	
0.896). However, preincubation with H-89 abolished cicaprost-
mediated IP3 production (Fig. 4B, p  0.0001) such that the
levels of IP3 generation were not significantly different to those
levels generated in control, nontransfected HEK 293 cells fol-
lowing cicaprost stimulation (p 	 0.25).
To extend these studies, we also investigated cicaprost-in-
duced PLC activation by monitoring mobilization of [Ca2]i.
Consistent with previous studies (12), stimulation of HEK.mIP
cells with cicaprost resulted in efficient transient rises in
[Ca2]i mobilization (Fig. 5A). Preincubation of HEK.mIP cells
with PTx (Fig. 5B) prior to stimulation with cicaprost had no
significant effect on [Ca2]i mobilization (p 	 0.627). Consist-
ent with this, transient overexpression of the carboxyl-terminal
residues (amino acid residues 459–689) of ARK1 (25) to se-
quester G subunits had no significant effect on cicaprost-
induced [Ca2]i mobilization (Fig. 5C, p 	 0.32). Overexpres-
sion of the carboxyl-terminal residues of ARK1 was confirmed
by Western blot analysis (Fig. 5D). Preincubation of HEK.mIP
cells with the PKC inhibitor GF 109203X had no significant
effect on [Ca2]i mobilization by the mIP (Fig. 5E, p 	 0.24). In
contrast, preincubation of HEK.mIP cells with H-89 resulted in
near complete inhibition of cicaprost-induced [Ca2]i mobiliza-
tion (Fig. 5F, p  0.001).
Thereafter to confirm that the source of cicaprost-induced
[Ca2]i mobilization is derived from PLC/IP3-regulated intra-
cellular Ca2stores, we examined the effect of the PI-PLC
inhibitor U73122 and, as a control, the phosphatidylcholine-
specific phospholipase C inhibitor D-609 (31, 32) on cicaprost-
induced [Ca2]i mobilization. Preincubation of HEK.mIP cells
with U73122 abolished [Ca2]i mobilization by the mIP (Fig.
6B, p  0.0001), whereas preincubation of the cells with D-609
had no significant effect on cicaprost-induced [Ca2]i mobiliza-
tion (Fig. 6C, p 	 0.07). As an additional control, preincubation
of HEK.mIP cells with U73122 did not affect ionomycin-in-
duced [Ca2]i mobilization ensuring that U73122 did not affect
the general measurement of [Ca2]i mobilization in Fura2/AM-
preloaded cells per se (p  0.001, data not shown).
Whole Cell Phosphorylations of the mIP—To establish
whether the mIP may be subject to cicaprost-induced PKA
phosphorylation, whole cell phosphorylations of the mIP were
investigated in HEK 293 cells stably overexpressing an amino-
terminal extracellular HA epitope-tagged mIP (HEK.HAmIP
cells). Consistent with previous reports (12, 33) and Table I, the
presence of the HA epitope tag did not affect the ligand binding
characteristics or cell signaling properties of mIP (data not
shown). Initially the specificity of the anti-HA 101R antiserum
to immunoprecipitate HAmIP from HEK.HAmIP cells and not
from HEK 293 cells (Fig. 7C) or HEK.mIP cells (data not
shown) was confirmed. Short term exposure of the Western blot
revealed the presence of two distinct immunoreactive bands
(Fig. 7C, lane 1), one between 46 and 66 kDa and the other
TABLE I
Radioligand binding assays
Cell type [3H]Iloprost bounda
pmol mg
1 protein
HEK.mIP 3.28  0.22
MEL 0.55  0.02
HEK.mIPSSLC 3.43  0.47
HEK.HAmIP isolate 1 2.37  0.12
HEK.HAmIP isolate 2 1.56  0.21
HEK.HAmIPS357A 1.57  0.24
HEK 293 0.01  0.001
Cell type [3H]CGP-12177 boundb
fmol mg
1 protein
HEK.2AR 92.2  5.0
HEK 293 15.0  1.2
a Radioligand binding assays were carried out on membrane fractions
of MEL cells, HEK 293 cells, or HEK 293 cells stably overexpressing
either mIP (HEK.mIP cells), mIPSSLC (HEK.mIPSSLC cells), HA-tagged
mIP (HEK.HAmIP isolates 1 and 2), or HA-tagged mIPS357A
(HEK.HAmIPS357A) in the presence of 4 nM [3H]iloprost.
b Radioligand binding assays were carried out on whole HEK 293
cells or on HEK 293 cells stably overexpressing the 2AR (HEK.2AR
cells) in the presence of 25 nM [3H]CGP-12177. Data are presented as
the mean  S.E. (n  4).
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between 36 and 46 kDa, corresponding to the glycosylated and
nonglycosylated forms of mIP, respectively (12, 33), which ap-
peared as a single broad band of 36–66 kDa following pro-
longed exposure (data not shown). In 32P metabolically labeled
cells, cicaprost resulted in phosphorylation of a broad protein
band of 36–66 kDa, corresponding to the immunoprecipitated
HAmIP in HEK.HAmIP cells (Fig. 7A, lane 2). In contrast, no
phosphorylation of mIP occurred in vehicle-treated, nonstimu-
lated HEK.HAmIP cells (Fig. 7A, lane 1) or in cicaprost-stim-
ulated HEK 293 control cells (Fig. 7A, lane 5). Whereas prein-
cubation of HEK.HAmIP cells with the PKC inhibitor GF
109203X did not significantly affect cicaprost-mediated mIP
phosphorylation (Fig. 7A, lane 3; p 	 0.05), preincubation of
HEK.HAmIP cells with the PKA inhibitor H-89 (Fig. 7B, lane
4) abolished cicaprost-induced HAmIP phosphorylation (p 
0.05).
The Role of the C-tail of the mIP in Receptor:G Protein Cou-
pling—It has previously been established that the isoprenyla-
tion-defective mIPSSLC, in which the critical Cys414 of mIP was
mutated to Ser414 to generate mIPS414SLC, cannot couple to Gs
to mediate cAMP increases and cannot efficiently couple to
Gq:PLC activation (12) implying that the C-tail of the mIP
may be important in receptor:G protein coupling. Thus, we
sought to investigate whether the isoprenylation-defective
mIPSSLC can couple to Gi. Consistent with previous studies
(12), HEK.mIPSSLC cells exhibited a significantly impaired
ability to generate cicaprost-mediated cAMP generation com-
pared with HEK.mIP cells (Fig. 8, compare panel A to panel C).
In fact the levels of cicaprost-induced cAMP generation in
HEK.mIPSSLC cells were not significantly different from that
produced by the control, nontransfected HEK 293 cells over the
range of 1 pM–100 nM cicaprost (data not shown), but at 1 M
cicaprost a small, although significant, increase in cAMP gen-
eration was observed in HEK.mIPSSLC cells (Fig. 8A, p  0.05).
Moreover, in the presence of forskolin, cicaprost (1 M) did not
result in a diminution of cAMP levels, indicative of Gi cou-
pling, in HEK.mIPSSLC cells (p 	 0.65) but rather showed a
marginal augmentation in cAMP generation (Fig. 8A). H-89
had no effect on the level of Gs or Gi coupling by mIP
SSLC
(Fig. 8B), but consistent with previous data (Fig. 2B) it signif-
FIG. 1. Agonist-induced cAMP generation. HEK.mIP cells (panel A) and MEL cells (panel B) were stimulated with either 1 M cicaprost, 10
M forskolin (Fsk), or 1 M cicaprost plus 10 M forskolin (Cic  Fsk). Alternatively, HEK.2AR cells (panel C) were stimulated with either 10 M
isoproterenol (Iso), 10 M forskolin (Fsk), or 10 M isoproterenol plus 10 M forskolin (Iso  Fsk). In each case, basal cAMP levels were determined
by exposing the cells to the vehicle under identical reaction conditions. Levels of cAMP produced in ligand-stimulated cells relative to basal cAMP
levels were expressed as -fold stimulation of basal (-fold increase in cAMP  S.E., n  4). Basal levels of cAMP generation in HEK.mIP cells and
in MEL cells were 0.71  0.04 pmol/mg of cell protein (n  4) and 0.98  0.06 pmol/mg of cell protein (n  4), respectively.
FIG. 2. The effect of kinase inhibitors on cicaprost-induced cAMP generation. HEK.mIP cells (panel A) were stimulated with either 1
M cicaprost, 10 M forskolin (Fsk), or 1 M cicaprost plus 10 M forskolin (Cic  Fsk) or were preincubated with PTx (50 ng/ml, 16 h) prior to
stimulation with 1 M cicaprost plus 10 M forskolin (Cic Fsk PTx). HEK.2AR cells (panel D) were stimulated with either 10 M isoproterenol
(Iso), 10 M forskolin (Fsk), or 10 M isoproterenol plus 10 M forskolin (Iso  Fsk) or were preincubated with PTx (50 ng/ml, 16 h) prior to
stimulation with 10 M isoproterenol plus 10 M forskolin (Iso  Fsk  PTx). Alternatively HEK.mIP cells (panels B and C) or HEK.2AR cells
(panels E and F) were preincubated for 10 min with 10 M H-89 (panels B and E) or 50 nM GF 109203X (GF) (panels C and F) prior to stimulation
with ligand as outlined in panels A and D, respectively. In each case, basal cAMP levels were determined by exposing the cells to the vehicle HBS
under identical reaction conditions. Levels of cAMP produced in ligand-stimulated cells relative to basal cAMP levels were expressed as -fold
stimulation of basal (-fold increase in cAMP  S.E., n  4). Basal levels of cAMP generation in HEK.mIP cells and in HEK.2AR cells were 0.81 
0.03 pmol/mg of cell protein (n  4) and 0.74  0.05 pmol/mg of cell protein (n  4), respectively.
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icantly impaired mIP coupling to Gi (Fig. 8D). To exclude the
possibility that the inability of the mIPSSLC to generate cAMP
is not due to low levels of IP, radioligand binding assays were
carried out on HEK.mIPSSLC membranes (Table I). No signifi-
cant differences were observed between the levels of mIP ex-
pression in HEK.mIP and HEK.mIPSSLC cells (p 	 0.0985).
Computational analysis of the C-tail region of the IP re-
vealed a putative PKA phosphorylation site in the mIP se-
quence where Ser357 represents the predicted target residue for
PKA phosphorylation (34). Thus, to determine the importance
of this potential PKA phosphorylation motif, site-directed mu-
tagenesis was used to generate mIPS357A, a variant of mIP in
which Ser357 was converted to Ala357, thereby destroying the
putative PKA phosphorylation site within the C-tail of mIP.
Stable cell lines overexpressing the epitope-tagged (HA)
mIPS357A (HEK.HAmIPS357A) were established and character-
ized by radioligand binding (Table I). Whereas through tran-
sient expression studies it was established that mutation of
Ser357 did not affect the ligand binding characteristics of the
mIPS357A compared with the wild type mIP, the level of
mIPS357A expression in HEK.HAmIPS357A cells was apprecia-
bly lower than that of mIP expressed in HEK.mIP or in HEK-
.HAmIP cells (Table I). Thus, to ensure that any potential
difference in the signaling behavior of the mIPS357A when com-
pared with the mIP may not be due to simple differences in the
relative levels of the respective receptor expression, for further
studies we chose to use a second pure clonal cell line or isolate
of the HEK.HAmIP cells (HEK.HAmIP isolate 2) that exhibited
similar levels of mIP expression to that of the HEK.
HAmIPS357A cells (Table I). Both the HEK.HAmIP and
HEK.HAmIPS357A cells showed significant cicaprost-mediated,
concentration-dependent increases in cAMP generation (Fig.
9A). Moreover, co-transfection of cells with Gs (Fig. 9B) sig-
nificantly augmented cAMP generation in HEK.HAmIP cells
(p  0.003) and in HEK.HAmIPS357A cells (p  0.0001) where
Gs overexpression was confirmed by Western blot analysis
(Fig. 9B, inset). However, whereas mIPS357A exhibited efficient
Gs coupling (p  0.001) unlike that of the mIP isolates, it did
not exhibit Gi coupling as evidenced by its failure to reduce,
but rather augmented, cAMP levels in cells co-stimulated with
cicaprost plus forskolin when compared with cells incubated
with forskolin alone (Fig. 9C). cAMP generation by the
mIPS357A was not affected by the presence of H-89 (Fig. 9D) or
GF 109203X (data not shown).
Next the ability of mIPS357A to couple to Gq and PLC acti-
vation was examined. HEK.HAmIP cells produced a concentra-
tion-dependent increase in IP3 generation upon stimulation
with 1 nM–10 M cicaprost (Fig. 10A, p  0.001 at 10 M
cicaprost). In contrast, neither the HEK.HAmIPS357A or the
nontransfected HEK 293 cells showed any significant increases
in IP3 even at the highest concentration used (p 	 0.249 at 10
M and p 	 0.314 at 10 M, respectively). Moreover, co-trans-
fection of cells with Gq did not augment cicaprost-mediated
IP3 generation in HEK.HAmIP
S357A cells (data not shown).
Stimulation of both the mIP and the mIPS357A did lead to
significant increases in [Ca2]i mobilization (Fig. 10B); how-
ever, the level of [Ca2]i mobilization by the mIP
S357A was
significantly less than that of the mIP (p 0.003) and was only
marginally greater than that mobilized in nontransfected HEK
293 cells in response to cicaprost (Ref. 12 and data not shown).
Whole Cell Phosphorylations of the mIPS357A—Whole cell
phosphorylations in HEK.HAmIPS357A cells (Fig. 7B) con-
FIG. 3. The effect of cicaprost concentration on mIP-induced cAMP generation. HEK.mIP cells were stimulated with cicaprost (1 pM–1
M) in the presence () or absence (
) of 10 M forskolin (Fsk) (panel A). Alternatively, HEK.mIP cells were preincubated with PTx (50 ng/ml, 16 h)
or with H-89 (10 M, 10 min) prior to stimulation with 1 pM–1 M cicaprost in the presence of 10 M forskolin (panel B). In each case, basal cAMP
levels were determined by exposing the cells to the vehicle under identical reaction conditions. Levels of cAMP produced in ligand-stimulated cells
relative to basal cAMP levels were expressed as -fold stimulation of basal (-fold increase in cAMP S.E., n 4). The basal level of cAMP generation
in HEK.mIP cells was 0.79  0.04 pmol/mg of cell protein (n  4).
FIG. 4. The effect of kinase inhibitors on cicaprost-induced IP3 generation in HEK.mIP cells. HEK.mIP cells (panel A) and HEK.mIP
cells transiently co-transfected with Gq (panel B) were stimulated with 1 M cicaprost or were preincubated with PTx (50 ng/ml, 16 h), GF
109203X (GF) (50 nM, 10 min), or H-89 (10 M, 10 min) prior to stimulation with 1 M cicaprost. In each case, basal IP3 levels were determined
by exposing the cells to the vehicle HBS under identical reaction conditions. Levels of IP3 produced in ligand-stimulated cells relative to
vehicle-treated cells (basal IP3) were expressed as -fold stimulation of basal (-fold increase in IP3  S.E., n  4). Panel C represents a typical
Western blot confirming overexpression of Gq in HEK.mIP cells (75 g of total cellular protein analyzed). Basal levels of IP3 generation in
HEK.mIP cells and in HEK.mIP cells transiently co-transfected with Gq were 0.36 0.04 pmol/mg of cell protein (n 4) and 0.49 0.04 pmol/mg
of cell protein (n  4), respectively.
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firmed that HAmIPS357A did undergo increased phosphoryla-
tion, represented as a broad phosphoprotein band of 36–66
kDa, in response to stimulation with cicaprost (Fig. 7B, com-
pare lanes 1 and 2). However, the level of HAmIPS357A phos-
phorylation was not significantly different from that observed
in HEK 293 cells (Fig. 7A, lane 5; p 	 0.05) but was substan-
tially less when compared with that of the HAmIP (Fig. 7,
compare panel A, lane 2 to panel B, lane 2; p 0.05) despite the
fact that HAmIPS357A was expressed at levels similar to that of
the HAmIP (Fig. 7C, lanes 1 and 2; Table I). Moreover, prein-
cubation of HEK.HAmIPS357A cells with GF 109203X or H-89
(Fig. 7B, lanes 3 and 4, respectively) had no effect on the level
of mIPS357A phosphorylation in cicaprost-stimulated cells.
mIP and mIPS357A Receptor:G Protein Interactions—To
investigate the G protein interactions of the mIP and the
mIPS357A more closely, HEK.HAmIP (Fig. 11A) and HEK.HA-
mIPS357A (Fig. 11B) cells were transiently transfected with
the cDNA encoding the  subunit of Gs (Fig. 11, panels A
and B, lanes 1 and 2), Gi (Fig. 11, panels A and B, lanes 3
and 4), or Gq (Fig. 11, panels A and B, lanes 5 and 6).
Receptor:G protein interactions were examined by immu-
noprecipitating the HAmIP or HAmIPS357A receptor using
FIG. 5. Effect of protein kinase in-
hibitors on [Ca2]i mobilization in
HEK.mIP cells. HEK.mIP cells (panel A)
or HEK.mIP cells preincubated with PTx
(50 ng/ml, 16 h) (panel B) were stimulated
with 1 M cicaprost. HEK.mIP cells were
transiently co-transfected with the cDNA
for the ARK1 C-tail (residues 459–689)
(panel C) or were preincubated for 10 min
with 50 nM GF 109203X (GF) (panel E) or
10 M H-89 (panel F) prior to stimulation
with 1 M cicaprost. In each case, cica-
prost was added at the time indicated by
the arrows. Data were calculated as
changes in intracellular Ca2 mobilized
([Ca2]i  S.E., nM) as a function of time
following ligand stimulation, and the data
presented are representative of at least
three independent experiments. Actual
changes in [Ca2]i mobilized were as fol-
lows: panel A, [Ca2]i  130  10.9 nM;
panel B, [Ca2]i  121  14.4 nM; panel
C, [Ca2]i  143  3.58 nM, panel E:
[Ca2]i  126  9.4 nM; panel F,
[Ca2]i  27.3  5.57 nM. Aliquots (75
g/lane) of HEK.mIP cells (
) or HEK.
mIP cells transiently co-transfected with
the cDNA for the ARK1 C-tail () were
screened by Western blot analysis using
the anti-ARK1 antibody as described un-
der “Experimental Procedures” (panel D).
These data are representative of three in-
dependent experiments.
FIG. 6. Effect of PLC inhibitors on [Ca2]i mobilization in HEK.mIP cells. HEK.mIP cells (panel A) or HEK.mIP cells preincubated for
5 min with 1 M U73122 (panel B) or 10 M D-609 (panel C) were stimulated with 1 M cicaprost where cicaprost was added at the times indicated
by the arrows. Data were calculated as changes in intracellular Ca2 mobilized ([Ca2]i  S.E., nM) as a function of time following ligand
stimulation and are representative of at least three independent experiments. Actual changes in [Ca2]i mobilized were as follows: panel A,
[Ca2]i  143  1.84 nM; panel B, [Ca
2]i  6.67  3.33 nM; panel C, [Ca
2]i  133  11.9 nM.
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the anti-HA 101R antisera followed by screening the immu-
noprecipitates for co-precipitation of the respective G subu-
nit using anti-G-specific antisera. Whereas nonstimulated,
vehicle (HBS)-treated cells showed no receptor:G protein in-
teraction (data not shown), stimulation of both HEK.HAmIP
and HEK.HAmIPS357A cells with cicaprost (1 M) for 10 min
permitted co-precipitation of Gs. However, whereas stimu-
lation of HEK.HAmIP cells with cicaprost resulted in co-prec-
ipitation of HAmIP with Gi and Gq, precipitation of neither
Gi nor Gq along with HAmIP
S357A was observed. The
presence of HAmIP and HAmIPS357A in the immunoprecipi-
tates was confirmed by screening the blots with the anti-
HA 3F10 horseradish peroxidase-conjugated antibody (data
not shown). Moreover, pretreatment of HEK.HAmIP cells
with H-89 blocked co-precipitation of Gi (Fig. 11C, lanes 3
and 4) and Gq (Fig. 11C, lanes 5 and 6) but had no effect
on co-precipitation of Gs along with HAmIP (Fig. 11C, lanes
1 and 2).
DISCUSSION
Prostacyclin is central to the regulation of vascular hemosta-
sis and may also mediate other somewhat diverse cellular
actions under both physiologic and pathophysiologic settings
(3, 8, 35). Mice deficient in the IP exhibit altered pain percep-
tion and inflammatory reactions as well as exhibiting an im-
paired response to thrombotic stimuli (4). Whereas IP is pri-
marily coupled to Gs-dependent adenylyl cyclase activation,
ligand activation of multiple signaling pathways by IP agonists
has been identified, such as in mouse BNu2cl3 mast cells (36),
in mouse preadipocyte Ob1771 cells (37), in human erythroleu-
FIG. 7. Cicaprost-induced phosphorylation of the mIP and mIPS357A. Panels A and B, HEK.HAmIP isolate 2 cells (panel A, lanes 1–4),
HEK.HAmIPS357A cells (panel B), or control HEK 293 cells (panel A, lane 5) metabolically labeled with [32P]orthophosphate were incubated for 10
min with the vehicle HBS (panels A and B, lane 1) or were stimulated for 10 min with 1 M cicaprost (panels A and B, lanes 2 and 5). Additionally,
HEK.HAmIP isolate 2 cells and HEK.HAmIPS357A cells were preincubated with 50 nM GF 109203X (panels A and B, lane 3) or 10 M H-89 (panels
A and B, lane 4) for 10 min prior to stimulation with 1 M cicaprost for 10 min. Thereafter HA epitope-tagged IP receptors were immunoprecipitated
using the anti-HA antibody 101R. Immunoprecipitates were resolved by SDS-PAGE, electroblotted onto PVDF membranes, and then exposed to
Xomat XAR-5 film (Kodak) for 8–10 days. Thereafter blots were subjected to PhosphorImage analysis, and the intensities of cicaprost-mediated
mIP and mIPS357A phosphorylation relative to basal phosphorylation in the presence of HBS were determined and expressed in arbitrary units as
follows: mIP: 1 M cicaprost, 11.2-fold; 1 M cicaprost plus 50 nM GF 109203X, 9.1-fold; 1 M cicaprost plus 10 M H-89, 1-fold; mIPS357A: 1 M
cicaprost, 1.51-fold; 1 M cicaprost plus 50 nM GF 109203X, 2.8-fold; 1 M cicaprost plus 10 M H-89, 1.9-fold; HEK 293: 1 M cicaprost, 1.23-fold.
Panel C, HEK.HAmIP isolate 2 (lane 1), HEK.HAmIPS357A (lane 2), or control HEK 293 (lane 3) cells were subjected to immunoprecipitation using
the anti-HA antibody 101R, and immunoprecipitates were resolved by SDS-PAGE and electroblotted onto PVDF membranes. Membranes were
screened using the anti-HA 3F10 horseradish peroxidase-conjugated antibody, and immunoreactive bands were visualized by chemiluminescence
detection. The positions of the molecular weight markers (kDa) are indicated to the left and right of panels A and C, respectively. Data presented
are representative of three independent experiments.
FIG. 8. Cicaprost-induced cAMP
generation by the mIPSSLC. HEK.
mIPSSLC (panels A and B) or HEK.mIP
(panels C and D) cells preincubated for 10
min in the absence (panels A and C) or
presence of 10 M H-89 (panels B and D)
were stimulated with either 1 M cica-
prost, 10 M forskolin (Fsk), or 1 M cica-
prost plus 10 M forskolin (Cic  Fsk). In
each case, basal cAMP levels were deter-
mined by exposing the cells to the vehicle
under identical reaction conditions. Lev-
els of cAMP produced in ligand-stimu-
lated cells relative to basal cAMP levels
were expressed as -fold stimulation of ba-
sal (-fold increase in cAMP  S.E., n  4).
Basal levels of cAMP generation in HEK.
mIPSSLC cells and in HEK.mIP cells were
0.83 0.04 pmol/mg of cell protein (n 4)
and 0.71  0.04 pmol/mg of cell protein
(n  4), respectively.
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kemia cells (13, 15, 38), and in human megakaryoblastic leu-
kemia (MEG01) cells (39). Coupling of IP to changes in intra-
cellular Ca2, rather than to activation of adenylyl cyclase, has
been reported in rabbit cortical collecting ducts (40), whereas
the IP expressed in the rat medullary thick ascending limb
coupled exclusively to Gi-mediated inhibition of adenylyl cycla-
ses rather than to Gs-mediated adenylyl cyclase activation (16).
Whereas molecular cloning has confirmed the existence of sin-
gle IPs in human, mouse, rat, and bovine tissues (11, 41–43),
the cloned human and mouse IP are reported to couple to
activation of both adenylyl cyclase and PLC effectors (10–13,
41). To date, IP isoforms are not known to exist unlike other
prostanoid receptors, and thus it appears that differential
mRNA splicing mechanisms per se cannot account for the mul-
tiple patterns of IP signaling within a given species (3, 44).
Thus, the key objective of the present study was to investigate
the molecular mechanisms whereby a single IP may couple to
more than one G protein:effector system by examining in detail
the signaling properties of the mIP either stably overexpressed
in HEK 293 (HEK.mIP) cells or in native MEL cells.
Consistent with mIP coupling to Gs, stimulation of HEK.
mIP and MEL cells resulted in significant cicaprost-induced
increases in cAMP generation. However, contrary to previous
reports, mIP expressed in both cell types also coupled to inhi-
bition of adenylyl cyclase in a PTx-sensitive, Gi-dependent
manner (data relating to PTx studies in MEL cells are not
shown). The PKA inhibitor H-89 abolished mIP:Gi coupling in
HEK.mIP cells but had no effect on mIP:Gs coupling. On the
FIG. 9. The effect of kinase inhibitors on cicaprost-induced cAMP generation by the mIPS357A. HEK.HAmIP isolate 2 (IP) and
HEK.HAmIPS357A (IPS357A) cells were stimulated with 1 pM–1 M cicaprost (panel A). Alternatively HEK.HAmIP isolate 2 (IP) and
HEK.HAmIPS357A (IPS357A) cells that had been transiently co-transfected with either the vector pCMV5 (
) or with the cDNA for Gs () were
stimulated with 1 M cicaprost (panel B). The inset to panel B represents a typical Western blot confirming overexpression of Gs in HEK.HAmIP
isolate 2 cells (75 g of total cellular protein analyzed) and in HEK.HAmIPS357A cells (data not shown). HEK.HAmIPS357A cells (panel C) and
HEK.HAmIPS357A cells preincubated for 10 min with 10 M H-89 (panel D) were stimulated with either 1 M cicaprost, 10 M forskolin (Fsk), or
1 M cicaprost plus 10 M forskolin (Cic  Fsk). In each case, basal cAMP levels were determined by exposing the cells to the vehicle HBS under
identical reaction conditions. Levels of cAMP produced in ligand-stimulated cells relative to basal cAMP levels were expressed as -fold stimulation
of basal (-fold increase in cAMP  S.E., n  4). Basal levels of cAMP generation in HEK.HAmIP isolate 2 (IP) and HEK.HAmIPS357A (IPS357A) cells
were 0.53  0.05 pmol/mg of cell protein (n  4) and 0.79  0.06 pmol/mg of cell protein (n  4), respectively.
FIG. 10. Cicaprost-induced IP3 generation and [Ca
2]i mobilization by the mIP
S357A. Panel A, HEK.HAmIP isolate 2 (IP),
HEK.HAmIPS357A (IPS357A), and HEK 293 (HEK) cells were stimulated with cicaprost (1 nM–10 M), and the levels of IP3 generation were measured
(panel A). In each case, basal IP3 levels were determined by exposing the cells to the vehicle HBS under identical reaction conditions. Levels of IP3
produced in ligand-stimulated cells relative to basal levels were expressed as -fold stimulation of basal (-fold increase in IP3  S.E., n  4). Basal
levels of IP3 generation in HEK.HAmIP isolate 2 (IP) cells, in HEK.HAmIP
S357A (IPS357A) cells, and in nontransfected HEK 293 (HEK) cells were
0.37 0.03 pmol/mg of cell protein (n 4), 0.39 0.04 pmol/mg of cell protein (n 4), and 0.29 0.03 pmol/mg of cell protein (n 4), respectively.
Panel B, HEK.HAmIP isolate 2 (IP) and HEK.HAmIPS357A (IPS357A) were stimulated with 1 M cicaprost, and [Ca2]i mobilization was measured
where cicaprost was added at the time indicated by the arrow (panel B). Data were calculated as changes in intracellular Ca2 mobilized ([Ca2]i
 S.E., nM) as a function of time following ligand stimulation, and data presented are representative of at least three independent experiments.
Actual changes in [Ca2]i mobilized were as follows in panel B: HEK.HAmIP cells, [Ca
2]i  112  3.41 nM; HEK.mIP
S357A cells, [Ca2]i 
55.3  2.57 nM.
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other hand, the PKC inhibitor GF 109203X had no effect on
mIP coupling to either Gs or Gi. To establish whether the
specificity of mIP coupling to Gs or Gi was concentration-de-
pendent, HEK.mIP cells were stimulated with a range of cica-
prost concentrations in the absence and presence of forskolin.
In the absence of forskolin, mIP generated significant, concen-
trationdependent increases in measurable cAMP consistent
with its coupling to Gs. However, in the presence of forskolin,
stimulation of mIP with low concentrations of cicaprost (1 nM)
generated significant concentration-dependent increases in
measurable cAMP consistent with its coupling to Gs, whereas
at higher concentrations (	1 nM) cicaprost yielded a concentra-
tiondependent reduction in cAMP generation indicative of mIP
coupling to Gi. Preincubation with PTx or H-89, but not GF
109203X (data not shown), blocked mIP-mediated Gi coupling
but had no effect on mIP coupling to Gs over the range of
cicaprost concentrations used. Taken together these data indi-
cate that mIP can couple to both Gs and to PTx-sensitive Gi
to mediate activation and inhibition of adenylyl cyclase, respec-
tively. Coupling of mIP to Gi, but not Gs, appears to require
a critical concentration of cAMP and is dependent on PKA
activation.
We extended our studies to investigate the mechanism
whereby the Gs-coupled mIP may also couple to PLC activation.
Cicaprost stimulation of HEK.mIP cells led to significant in-
creases in IP3 generation and mobilization of [Ca
2]i. H-89, but
not PTx or GF 109203X, almost completely abolished cicaprost-
mediated signaling indicating that mIP-mediated IP3 genera-
tion and [Ca2]i mobilization occurred in a PTx-insensitive,
PKC-independent, PKA-dependent mechanism(s). Moreover,
overexpression of the carboxyl-terminal residues of ARK1, to
sequester G subunits, confirmed that cicaprost-mediated IP3
generation (data not shown) or [Ca2]i mobilization were not
through G-stimulated mechanisms such as through G reg-
ulation of PLC isozymes (45). Consistent with these data,
transient overexpression of Gq led to significant augmenta-
tions of cicaprost-mediated IP3 generation and mobilization of
[Ca2]i (Ref. 12 and data not shown) in a PTx-insensitive,
PKC-independent, PKA-dependent mechanism(s). Further-
more, the PI-PLC inhibitor U73122 (32) abolished cicaprost-
induced [Ca2]i mobilization confirming that the primary
source of mIP-mediated [Ca2]i mobilization is from IP3-regu-
lated intracellular stores. Thus, taken together these data in-
dicate that mIP, in addition to coupling to Gs and Gi, can couple
to PLC and that PLC coupling occurs in a Gq-mediated, PTx-
insensitive, PKC-independent, but PKA-dependent, manner.
Additionally, coupling of mIP to both Gi and Gq is dependent on
its prior coupling to Gs to stimulate cAMP-dependent PKA
activation. Moreover, subsequent whole cell phosphorylation
assays established that the mIP is subject to cicaprost-medi-
ated phosphorylation in a GF 109203X-independent, H-89-de-
pendent manner indicating that mIP coupling to Gi and Gq
may involve direct PKA-mediated phosphorylation of the mIP
itself.
We have previously established that mIP may be unique
among GPCRs in that it is isoprenylated within its C-tail
domain (12, 13). Disruption of isoprenylation through site-
directed mutagenesis to generate mIPSSLC established that
isoprenylation of mIP is required for its efficient Gs- and
Gq-mediated activation of adenylyl cyclase and PLC, respec-
tively, suggesting that the C-tail of the mIP may be involved in
receptor:G protein interaction (12). Consistent with previous
studies (12), the isoprenylation-defective mIPSSLC exhibited
significantly diminished coupling to both adenylyl cyclase and
PLC activation compared with the wild type mIP. Moreover,
mIPSSLC failed to couple to Gi to mediate inhibition of forsko-
lin-induced cAMP generation indicating that (a) the C-tail do-
main of mIP may be involved in receptor:Gi interaction and/or
that (b) failure of mIPSSLC to couple to Gi may be due to its
initial inability to couple to Gs to stimulate PKA-mediated
mIP phosphorylation and subsequent coupling to Gi and in-
deed to Gq.
Analysis of the primary sequence of the mIP revealed the
presence of a putative PKA phosphorylation site within the
C-tail region of the mIP where Ser357 represents the predicted
target residue for phosphorylation (34). Thus, through the use
of site-directed mutagenesis, the role of Ser357 was investi-
gated. Whereas mIPS357A exhibited Gs activation of adenylyl
FIG. 11. Co-immunoprecipitation of the mIP and mIPS357A with
their associated G subunits. HEK.HAmIP isolate 2 (panel A) and
HEK.HAmIPS357A (panel B) cells were transiently co-transfected for
48 h without (
) or with () the cDNA encoding Gs (panels A and B,
lanes 1 and 2), Gi (panels A and B, lanes 3 and 4), and Gq (panels A
and B, lanes 5 and 6). Alternatively HEK.HAmIP isolate 2 cells (panel
C) transiently co-transfected for 48 h with Gs (panel C, lanes 1 and 2),
Gi (panel C, lanes 3 and 4), and Gq (panel C, lanes 5 and 6) were
preincubated for 10 min with vehicle (
) or with 10 M H-89 ().
Thereafter cells were stimulated with 1 M cicaprost for 10 min, and HA
epitope-tagged receptors were immunoprecipitated using the anti-HA
antibody 101R. Immunoprecipitations were resolved by SDS-PAGE and
electroblotted onto PVDF membranes. Membranes were screened for
the presence of Gs (panels A–C, lanes 1 and 2), Gi (Panels A–C, lanes
3 and 4), or Gq (panels A–C, lanes 5 and 6) using the respective anti-G
subunit antisera essentially as described under ”Experimental Proce-
dures,“ and immunoreactive bands were visualized by chemilumines-
cence detection. Data presented are representative of three independ-
ent experiments. The positions of the molecular mass markers (kDa)
are indicated to the right of panels A–C.
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cyclase similar to that of the wild type mIP, it failed to couple
to Gi or to Gq to mediate inhibition of adenylyl cyclase and
activation of PLC, respectively. The fact that mIP, but not
mIPS357A, exhibited cicaprost-mediated Gi and Gq coupling
confirmed that cicaprost is acting through the mIP itself and
not through another, perhaps related prostanoid, receptor to
mediate these effects. Unlike that which occurred for the wild
type mIP, whole cell phosphorylation assays established that
mIPS357A did not undergo significant agonist-induced PKA
phosphorylation. Finally, cicaprost stimulation of cells overex-
pressing HA epitope-tagged forms of the mIP and mIPS357A
permitted co-immunoprecipitation of Gs confirming direct, ag-
onist-induced interaction of both mIP and mIPS357A with Gs.
On the other hand, whereas stimulation of HEK.HAmIP cells
with cicaprost resulted in co-precipitation of HAmIP with both
Gi and Gq, co-precipitation of neither Gi nor Gq along with
HAmIPS357A was observed. Furthermore, in support of this,
inhibition of PKA blocked co-precipitation of Gi and Gq with
HAmIP but had no effect on co-precipitation of Gs with
HAmIP suggesting that for mIP interaction with Gi and/or
Gq to occur mIP must be phosphorylated on Ser
357 by PKA.
Thus, taken together the data presented in this study provide
a mechanism whereby the classical Gs-coupled mIP may cou-
ple both to Gi-mediated inhibition of adenylyl cyclase and to
Gq-mediated activation of PLC. This mechanism, as outlined
in the model presented in Fig. 12, requires initial mIP coupling
to Gs leading to elevation of cAMP and PKA activation. There-
after PKA-mediated phosphorylation of mIP at Ser357 within
the C-tail domain of mIP in turn favors its coupling to Gi,
leading to inhibition of adenylyl cyclase, and to Gq, leading to
activation of PLC.
The proposed mechanism of mIP coupling to both Gs and to
Gi is not unlike that which has been previously reported for
the 2AR-mediated switching from Gs to Gi (21, 23). In their
model, the 2AR can switch coupling from Gs to Gi in a
mechanism involving initial Gs activation of adenylyl cyclase
and subsequent PKA phosphorylation within the third intra-
cellular loop of the 2AR; the phosphorylated 2AR, in turn,
exhibited diminished coupling to Gs and increased coupling to
Gi thereby switching its coupling from Gs to Gi. (21, 23, 46).
In our studies, we identified Ser357 within the C-tail of the mIP
itself as being the critical residue for PKA phosphorylation and,
hence, regulating the Gs to Gi coupling mechanism. Our
studies do not rule out the possibility that other components of
the signaling pathway may also be targets for the PKA-medi-
ated phosphorylation and contribute to the differential signal-
ing event; however, the fact that mIPS357A can couple effi-
ciently to Gs to generate cAMP and activate PKA but not to Gi
makes it unlikely that other signaling elements are involved.
One of the manifestations of the 2AR switching its coupling
from Gs is that the Gi-coupled receptor can stimulate activation
of the mitogen-activated protein kinase cascades in a PTx-
sensitive, G- and Src-mediated cascade (23). Whether a sim-
ilar mechanism applies to the Gi-coupled mIP will require
further investigation.
Many Gs-coupled GPCRs can activate both cAMP and IP3/
Ca2 signaling pathways, and three mechanisms have been
proposed to explain this dual G protein coupling. One mecha-
nism is independent GPCR coupling to Gs and to a Gq member,
such as G15 or G16, to initiate independent activation of adeny-
lyl cyclase and PLC (24). The other two mechanisms involve
cAMP-regulated PKA activation of PLC or PKA-induced
switching of receptor coupling from Gs to Gi (24). In the latter
mechanism, such as that reported to occur for the vasoactive
intestinal peptide receptor, both PLC-mediated IP3 generation
and mobilization of [Ca2]i are regulated through PTx-sensi-
tive, Gi-derived G subunits rather than through Gq-coupled
mechanisms (24). In our studies investigating mIP, as stated,
we established that PKA phosphorylation of Ser357 within the
C-tail of the mIP itself as the critical residue to regulate cou-
pling to both Gi and Gq; thereafter the phosphorylated mIP
can independently regulate Gi- and Gq-mediated inhibition of
adenylyl cyclase and activation of PLC, respectively. Thus, our
mechanism differs from that proposed for the vasoactive intes-
tinal peptide receptor in that mIP-mediated PLC activation is
PTx-insensitive, Gi- and G-independent. Moreover, mIP-me-
diated PLC activation occurs in a PKA-dependent, Gq-coupled
mechanism suggesting that mIP must undergo PKA-mediated
switching from Gs to Gq to activate PLC activation as opposed
to independently coupling to Gs and Gq members as proposed in
the first mechanism (24). Similar to that previously stated for
mIP:Gi coupling, our studies do not fully exclude the possibil-
ity that other components of the signaling pathway, such as
PLC, may also be targets for the PKA-mediated phosphoryl-
ation as proposed in the second mechanism (24); however, the
fact that mIPS357A can couple efficiently to Gs but does not
couple to Gq:PLC activation makes it unlikely.
Several GPCRs are known to activate dual or multiple sig-
naling systems, such as the thrombin receptor, the histamine
H2 receptor, or the parathyroid receptor to name but a few (47).
In many instances, this can occur in a species- or cell type-
specific manner. However, the molecular mechanisms whereby
a given GPCR may couple to multiple G protein-coupled effec-
tors are, on the whole, poorly understood. Our studies extend
those previously reported for the 2AR (23) and for the vaso-
active peptide receptor (24) and establish that second messen-
ger kinase-, such as PKA-mediated switching is not restricted
to Gs/Gi mechanisms but may also be extended to dual switch-
ing from Gs to both Gi and Gq mechanisms independently.
Moreover, our studies add further evidence to the growing
awareness that mechanisms such as GPCR phosphorylation
and internalization, previously thought to be exclusively asso-
FIG. 12. Model of mIP coupling to Gs-mediated activation of
adenylyl cyclase (AC) (a), Gi-coupled inhibition of adenylyl
cyclase (b), and Gq-coupled activation of PI-PLC (c). a, ligand
activation of the mIP stimulates Gs-mediated activation of adenylyl
cyclase leading to increases in cAMP generation and, in turn, activation
of PKA. b, activated PKA phosphorylates the mIP at Ser357 favoring
mIP:Gi coupling leading to decreases in adenylyl cyclase activity and,
in turn, decreases in cAMP generation. PKA-mediated mIP phospho-
rylation and coupling to PTx-sensitive Gi may be inhibited by H-89. c,
alternatively PKA-mediated phosphorylation of mIP at Ser357 may pro-
mote mIP:Gq coupling leading to activation of PI-PLC and, in turn,
leading to increases in IP3 generation and mobilization of [Ca
2]i.
PKA-mediated mIP phosphorylation and coupling to Gq may be inhib-
ited by H-89, and the PI-PLC inhibitor U73122 blocks mIP-mediated
IP3 generation and mobilization of [Ca
2]i.
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ciated with the desensitization of GPCR signaling, may trigger
activation of other signaling events, such as switching receptor
coupling from one G protein-coupled cascade to other G protein-
coupled cascade(s), or to initiation of other signaling events,
such as activation of mitogen-activated protein kinase cascades
and/or transactivation of growth factor signaling (21, 22).
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